Kane Robert C
Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA.
Oncologist. 2008 Nov;13(11):1129-33. doi: 10.1634/theoncologist.2008-0186. Epub 2008 Nov 4.
Modern clinical trials provide the evidence for most therapeutic advances, and that evidence, expressed in a statistical format, is used to draw inferences about a population from the study's results. Clinician judgment translates these inferences for best individual patient care, but many clinicians struggle with the statistical interpretation of trial results. This review provides a clinical and non-Bayesian perspective on some key elements in the statistical design, analysis, and interpretation of randomized, comparative, phase III clinical trials intended to demonstrate a better outcome (superiority) than with a control treatment.
现代临床试验为大多数治疗进展提供了证据,而以统计形式表达的这些证据被用于从研究结果中推断总体情况。临床医生的判断将这些推断转化为针对个体患者的最佳治疗,但许多临床医生在对试验结果进行统计学解释时存在困难。本综述从临床和非贝叶斯的角度,对旨在证明比对照治疗有更好结局(优越性)的随机、比较性III期临床试验的统计设计、分析和解释中的一些关键要素进行探讨。